Injections of Interleukins Around Tumor-Draining Lymph Nodes: A New Mode of Immunotherapy
There are two main kinds of immune strategy which can be used against neoplasia. The first potentiates a selected effector arm. In vitro culture of lymphocytes with exogenous interleukin-2 (IL-2) generates lymphokine-activa-ted killer (LAK) activity or leads to the expansion of T cytotoxic lymphocytes. Their reinfusion together with high doses of IL-2 mediates the regression of a variety of murine and human tumors (Rosenberg et al. 1986, 1987). Alternatively, the host immune system can be “helped” to recognize and react against the tumor itself. Here the therapeutic maneuver is regulatory.
KeywordsShrinkage Sarcoma Prostaglandin
Unable to display preview. Download preview PDF.
- Boraschi D, Nencioni L, Villa L, Censini S, Bossu’ P, Ghiara P, Presentini R, Perin F, Frasca D, Doria G, Forni G, Musso T, Giovarelli M, Ghezzi P, Bertini R, Besedovsky HO, del Rey A, Stipe JD, Antoni G, Silvestri S, Tagliabue A (1988) In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163–171 of the human IL-1 beta. J Exp Med 168:675–686PubMedCrossRefGoogle Scholar
- Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G (1988) Treatment of recurrent squamous cell carcinoma of head and neck with low doses of interleukin-2 (IL-2) injected perilymphatically. Cancer (in press)Google Scholar
- Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JJT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 316:889–893CrossRefGoogle Scholar